UK Medical Cannabis Registry: A Patient Evaluation.


Journal

Journal of pain & palliative care pharmacotherapy
ISSN: 1536-0539
Titre abrégé: J Pain Palliat Care Pharmacother
Pays: England
ID NLM: 101125608

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 9 6 2023
pubmed: 11 2 2023
entrez: 10 2 2023
Statut: ppublish

Résumé

The UK Medical Cannabis Registry is the largest real world data platform for medical cannabis outcomes in the UK, providing insight into clinical outcomes and monitoring safety of this novel therapy. This study aims to assess the functionality and accessibility of the online data collection platform and patient priorities for future research. Descriptive statistics were used to analyze quantitative data. For open-ended questions an inductive thematic analysis was performed. 600 responses were recorded. 554 (92.3%) patients had used the platform. 272 (90.4%) patients believed it was easy to input medications. 52 (8.67%) patients recorded an adverse event with 38 (73.1%) finding it easy to record. 535 (96.6%) patients had completed health questionnaires with 490 (91.6%) patients finding this easy to do. 553 (92.2%) patients agreed that contributing to the registry would impact the medical care of future patients. "Assessing the impact of medical cannabis on quality of life generally" was the top research priority for 357 (59.3%) patients. This study demonstrates that most enrolled patients found the platform easy to use and believed they were positively impacting future medical cannabis patient care. Future patient research priorities included assessment of quality of life and condition-specific outcomes.

Identifiants

pubmed: 36762986
doi: 10.1080/15360288.2023.2174633
doi:

Substances chimiques

Medical Marijuana 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

170-177

Auteurs

James Tait (J)

James Tait, BSc (Hons), Simon Erridge, MBBS, BSc (Hons), and Mikael H. Sodergren, FRCS, PhD, Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.

Simon Erridge (S)

James Tait, BSc (Hons), Simon Erridge, MBBS, BSc (Hons), and Mikael H. Sodergren, FRCS, PhD, Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Simon Erridge, and Mikael H. Sodergren, Sapphire Medical Clinics, London, UK.

Mikael H Sodergren (MH)

James Tait, BSc (Hons), Simon Erridge, MBBS, BSc (Hons), and Mikael H. Sodergren, FRCS, PhD, Imperial College Medical Cannabis Research Group, Department of Surgery and Cancer, Imperial College London, London, UK.
Simon Erridge, and Mikael H. Sodergren, Sapphire Medical Clinics, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH